Medical Research News

RSS

Tomophase to commercialize OCT Imaging System for pulmonary applications with QTDP award

Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced that it has received an award from the Departments of the Treasury and Health and Human Services for the Qualifying Therapeutic Discovery Project (QTDP.)

8 Nov 2010

Researchers take first step towards understanding of rare skin cancer

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Americans sicker but live longer than the English: Study

According to a new study in the journal Demographics, and elderly American is not quite as healthy as his English counterpart, but does live just as long, if not longer. The study found that Americans aged 55 to 64 and 70 to 80 had higher rates of chronic diseases than same-aged English people, but they died at about the same rate. Americans aged 65 and older could be sicker than their English peers but lived longer.

5 Nov 2010

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant.

4 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Higher-quality medical care in the U.S. than in England, says study

Older Americans are less healthy than their English counterparts, but they live as long or even longer than their English peers, according to a new study by researchers from the RAND Corporation and the Institute for Fiscal Studies in London.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

Benchmark adds Class III medical device manufacturing capabilities in Thailand

Benchmark Electronics, Inc., a leading integrated electronics manufacturing services (EMS) provider, announced its Thailand facility has successfully completed a full Quality System Inspection Technique (QSIT) audit from the Food and Drug Administration (FDA), through its premarket approval (PMA) supplement evaluation process, to manufacture Class III finished devices on behalf of large tier-one medical original equipment manufacturers (OEMs).

4 Nov 2010

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.

4 Nov 2010

Volunteering benefits older adults with functional limitations

Volunteering is known to provide health benefits to the person doing the volunteering. Now, a new study finds that older adults with functional limitations (trouble conducting daily tasks like cooking meals) in particular appear to reap the benefits from helping others.

4 Nov 2010

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

New radiotracer application may advance understanding of estrogen-related diseases

A study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has demonstrated that a molecule "tagged" with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. The research, published in the November issue of Synapse, also uncovered that the regions of the brain where aromatase is concentrated may be unique to humans.

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

Modified sugar compound protects against world's deadliest viruses

When a team of European researchers sought to discover how a class of antiviral drugs worked, they looked in an unlikely place: the sugar dish. A new research report appearing in the Journal of Leukocyte Biology suggests that a purified and modified form of a simple sugar chain may stop fast-acting and deadly viruses, such as Ebola, Lassa, or Marburg viruses, in their tracks.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has been awarded a grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The QTDP's grants and tax credits are provided under the new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Medical Research News

Tomophase to commercialize OCT Imaging System for pulmonary applications with QTDP award

Researchers take first step towards understanding of rare skin cancer

Skin to blood transformation in the lab

Americans sicker but live longer than the English: Study

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Higher-quality medical care in the U.S. than in England, says study

Athersys secures three Therapeutic Discovery Project grants

Antigenics awarded $424,720 grant under QTDP program

Benchmark adds Class III medical device manufacturing capabilities in Thailand

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Volunteering benefits older adults with functional limitations

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Scientists identify events that causes AD progression

New radiotracer application may advance understanding of estrogen-related diseases

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

New findings show combinational therapy effective for patients with DLBCL lymphoma

Modified sugar compound protects against world's deadliest viruses

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News